As of today (2024-04-26), Penumbra's share price is $204.41.
Penumbra's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.09. Hence, Penumbra's Price-to-Free-Cash-Flow Ratio for today is 97.71.
The historical rank and industry rank for Penumbra's Price-to-Free-Cash-Flow or its related term are showing as below:
PEN'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 96.9 Med: 538.52 Max: 1536.96
Current: 98.58
During the past 12 years, Penumbra's highest Price-to-Free-Cash-Flow Ratio was 1536.96. The lowest was 96.90. And the median was 538.52.
PEN's Price-to-Free-Cash-Flow is ranked worse than 85.71% of 336
companies
in the Medical Devices & Instruments industry
Industry Median: 31.345
vs PEN: 98.58
During the past 12 years, Penumbra's highest 3-Year average Free Cash Flow per Share Growth Rate was 46.00% per year. The lowest was -190.70% per year. And the median was -66.50% per year.
Penumbra Price-to-Free-Cash-Flow Historical Data
The historical data trend for Penumbra's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Penumbra's Price-to-Free-Cash-Flow
For the Medical Devices subindustry, Penumbra's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Penumbra's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Penumbra's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Penumbra's Price-to-Free-Cash-Flow falls into.
Penumbra Price-to-Free-Cash-Flow Calculation
Penumbra's Price-to-Free-Cash-Flow ratio for today is calculated as
Penumbra's Share Price of today is $204.41. Penumbra's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Penumbra Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Penumbra's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PEN has been successfully added to your 